<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793581</url>
  </required_header>
  <id_info>
    <org_study_id>IMAGE BTK</org_study_id>
    <nct_id>NCT04793581</nct_id>
  </id_info>
  <brief_title>Assessment of the Utility of the Pantheris Small Vessel (SV) System</brief_title>
  <official_title>Assessment of the Utility of the Pantheris SV System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avinger, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avinger, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm study to assess the utility of the Pantheris SV catheter in addressing&#xD;
      peripheral artery disease in arteries located below the knee. Data will be collected on the&#xD;
      percent stenosis pre- and post-atherectomy and then symptoms and adverse events noted at 30&#xD;
      days, 6 months, and 1 year after the procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post-market, single-arm study of the optical coherence tomography (OCT)-guided&#xD;
      directional atherectomy catheter, Pantheris SV. Patients presenting with reduced blood flow&#xD;
      in the lower extremity arteries will under directional atherectomy, followed by adjunctive&#xD;
      therapy as deemed necessary by the physician, and then adverse events and symptom resolution&#xD;
      will be documented at 30 days, 6 months, and 1 year after the procedure. Primary safety&#xD;
      endpoints are related to adverse events and will be assessed at the time of the procedure and&#xD;
      at 30 days after the procedure. Effectiveness endpoints center on restoration of blood flow.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>from procedure to 30 days post-procedure</time_frame>
    <description>freedom from cardiovascular-related events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical success</measure>
    <time_frame>At 1 day post-procedure</time_frame>
    <description>defined as residual stenosis &lt; 50% after atherectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>At 1 day post-procedure</time_frame>
    <description>defined as residual stenosis &lt; 30% post adjunctive therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from target vessel revascularization (TVR)</measure>
    <time_frame>At 6 and 12 months post-procedure</time_frame>
    <description>revascularization needed further</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency</measure>
    <time_frame>At 6 and 12 months post-procedure</time_frame>
    <description>change in peak systolic velocity ratio (PSVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial Index (ABI)</measure>
    <time_frame>At 6 and 12 months post-procedure</time_frame>
    <description>Improvement since index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford Classificaiton</measure>
    <time_frame>At 30 days, 6 months, and 1 year post-procedure</time_frame>
    <description>Change since index procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atherectomy</intervention_name>
    <description>Directional atherectomy of lesions below the knee.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Target lesion in the infragenicular segment&#xD;
&#xD;
          -  At least 1 pedal vessel noted in the foot&#xD;
&#xD;
          -  Rutherford classification 3 to 6&#xD;
&#xD;
          -  Willing to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  if female, is pregnant or breast feeding&#xD;
&#xD;
          -  has had surgery or endovascular procedure within 30 days prior to the index procedure&#xD;
&#xD;
          -  has planned surgery within 30 days after the index procedure&#xD;
&#xD;
          -  had a major bleeding event within 60 days prior to the index procedure&#xD;
&#xD;
          -  currently in the treatment phase of a drug or device trial&#xD;
&#xD;
          -  has anticipated life span of less than 1.5 years&#xD;
&#xD;
          -  is unwilling to present to the investigator at 30 days, 6 moths, or 1 year after the&#xD;
             index procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaafer Golzar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Avinger, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Lawson, PhD</last_name>
    <phone>6502417030</phone>
    <email>tlawson@avinger.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Lira, BS</last_name>
    <phone>6502417031</phone>
    <email>rlira@avinger.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Advanced Cardiac and Vascular Centers</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abby Mize, BS</last_name>
      <phone>616-447-8220</phone>
      <email>amize@acvcenters.com</email>
    </contact>
    <investigator>
      <last_name>Jihad Mustapha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastlake Cardiovascular PC</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rewaa Yas, MS</last_name>
      <phone>586-944-2800</phone>
      <phone_ext>522</phone_ext>
      <email>ryas@eastlakecv.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Khalili H, Jeon-Slaughter H, Armstrong EJ, Baskar A, Tejani I, Shammas NW, Prasad A, Abu-Fadel M, Brilakis ES, Banerjee S. Atherectomy in below-the-knee endovascular interventions: One-year outcomes from the XLPAD registry. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):488-493. doi: 10.1002/ccd.27897. Epub 2018 Nov 30.</citation>
    <PMID>30499198</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwindt AG, Bennett JG Jr, Crowder WH, Dohad S, Janzer SF, George JC, Tedder B, Davis TP, Cawich IM, Gammon RS, Muck PE, Pigott JP, Dishmon DA, Lopez LA, Golzar JA, Chamberlin JR, Moulton MJ, Zakir RM, Kaki AK, Fishbein GJ, McDaniel HB, Hezi-Yamit A, Simpson JB, Desai A. Lower Extremity Revascularization Using Optical Coherence Tomography-Guided Directional Atherectomy: Final Results of the EValuatIon of the PantheriS OptIcal COherence Tomography ImagiNg Atherectomy System for Use in the Peripheral Vasculature (VISION) Study. J Endovasc Ther. 2017 Jun;24(3):355-366. doi: 10.1177/1526602817701720. Epub 2017 Apr 10.</citation>
    <PMID>28393673</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral artery disease (PAD) below-the-knee atherectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

